As the U.S. looks on, European countries feel growing pressure on drug prices

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.LONDON — In Europe, two divergent paths are emerging as countries grapple with what to do about drug prices, affecting pharma companies and patients across the continent — and testing the influence of the U.S.

In the U.K., after a pressure campaign from both pharma companies and the Trump administration, the government has adopted more industry-friendly policies while also simply promising to spend more on medicines.

Germany, another of the continent’s biggest markets, is headed in the opposite direction. Facing growing deficits in its health budget, the government has proposed moves that would cut spending and increase the fees the industry has to pay.

STAT+ Exclusive Story

Already have an account? Log in